223 related articles for article (PubMed ID: 34639107)
21. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
Lewis CS; Voelkel-Johnson C; Smith CD
Oncotarget; 2016 Sep; 7(37):60181-60192. PubMed ID: 27517489
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.
Gestaut MM; Antoon JW; Burow ME; Beckman BS
Pharmacol Rep; 2014 Feb; 66(1):174-8. PubMed ID: 24905325
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
24. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth.
Dai L; Bai A; Smith CD; Rodriguez PC; Yu F; Qin Z
Mol Cancer Ther; 2017 Dec; 16(12):2724-2734. PubMed ID: 28939554
[TBL] [Abstract][Full Text] [Related]
25. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
[TBL] [Abstract][Full Text] [Related]
26. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
27. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF
Wang K; Li Y; Song N; Che X; Hou K; Xu L; Bai M; Wang Q; Wang Y; Zhou Y; Cao M; Liu Y; Zhang J
J Cell Biochem; 2019 Apr; 120(4):5315-5325. PubMed ID: 30320916
[TBL] [Abstract][Full Text] [Related]
28. Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression.
Dai L; Trillo-Tinoco J; Bai A; Chen Y; Bielawski J; Del Valle L; Smith CD; Ochoa AC; Qin Z; Parsons C
Oncotarget; 2015 Sep; 6(27):24246-60. PubMed ID: 26327294
[TBL] [Abstract][Full Text] [Related]
29. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.
Antoon JW; White MD; Meacham WD; Slaughter EM; Muir SE; Elliott S; Rhodes LV; Ashe HB; Wiese TE; Smith CD; Burow ME; Beckman BS
Endocrinology; 2010 Nov; 151(11):5124-35. PubMed ID: 20861237
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
32. Sphingosine kinase 2 inhibitor ABC294640 suppresses neuronal excitability and inhibits multiple endogenously and exogenously expressed voltage-gated ion channels in cultured cells.
Zhang F; Hu W; Qu L; Cang C
Channels (Austin); 2020 Dec; 14(1):216-230. PubMed ID: 32615066
[TBL] [Abstract][Full Text] [Related]
33. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.
Schrecengost RS; Keller SN; Schiewer MJ; Knudsen KE; Smith CD
Mol Cancer Res; 2015 Dec; 13(12):1591-601. PubMed ID: 26271487
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
37. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.
Guillermet-Guibert J; Davenne L; Pchejetski D; Saint-Laurent N; Brizuela L; Guilbeau-Frugier C; Delisle MB; Cuvillier O; Susini C; Bousquet C
Mol Cancer Ther; 2009 Apr; 8(4):809-20. PubMed ID: 19372554
[TBL] [Abstract][Full Text] [Related]
38. AKT as a key target for growth promoting functions of neutral ceramidase in colon cancer cells.
Coant N; García-Barros M; Zhang Q; Obeid LM; Hannun YA
Oncogene; 2018 Jul; 37(28):3852-3863. PubMed ID: 29662189
[TBL] [Abstract][Full Text] [Related]
39. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.
Garandeau D; Noujarède J; Leclerc J; Imbert C; Garcia V; Bats ML; Rambow F; Gilhodes J; Filleron T; Meyer N; Brayer S; Arcucci S; Tartare-Deckert S; Ségui B; Marine JC; Levade T; Bertolotto C; Andrieu-Abadie N
Mol Cancer Ther; 2019 Feb; 18(2):289-300. PubMed ID: 30482853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
